Trial reportAlimentary pharmacology & therapeutics2021
Fructan-sensitive children with irritable bowel syndrome have distinct gut microbiome signatures.
Trial report in Alimentary pharmacology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Effects of fructan and gluten on gut microbiota in individuals with self-reported non-celiac gluten/wheat sensitivity-a randomised controlled crossover trial.BMC medicine · 2024Trial
- Weight, habitual fibre intake, and microbiome composition predict tolerance to fructan supplementation.International journal of food sciences and nutrition · 2024Trial
- Efficacy of an eHealth self-management program in reducing irritable bowel syndrome symptom severity: a randomized controlled trial.Scientific reports · 2024Trial
- Inulin as a Modulator of the Intestinal Barrier: Experimental Evidence, Mechanisms and Clinical Implications.Biomedicines · 2026Review
- Bioactive compounds as therapeutic modulators of metabolic syndrome: targeting inflammation and gut microbiota regulation.Frontiers in physiology · 2026Review
- Protocol for a Randomized Controlled Trial to Determine if Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program.Journal of clinical medicine · 2025Article
- Role of microbiota in pain: From bench to bedside.iMetaOmics · 2025Review
- Chicoric Acid Effectively Mitigated Dextran Sulfate Sodium (DSS)-Induced Colitis in BALB/c Mice by Modulating the Gut Microbiota and Fecal Metabolites.International journal of molecular sciences · 2024Article
- Mendelian randomization analysis reveals an independent causal relationship between four gut microbes and acne vulgaris.Frontiers in microbiology · 2024Article
- From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes.Biomedicines · 2023Review
- Does sourdough bread provide clinically relevant health benefits?Frontiers in nutrition · 2023Review
- Perspective: Assessing Tolerance to Nondigestible Carbohydrate Consumption.Advances in nutrition (Bethesda, Md.) · 2022Article
- Fate and Transformation of 6:2 Fluorotelomer Sulfonic Acid Affected by Plant, Nutrient, Bioaugmentation, and Soil Microbiome Interactions.Environmental science & technology · 2022Article
- Non-Photosynthetic Melainabacteria (Cyanobacteria) in Human Gut: Characteristics and Association with Health.Life (Basel, Switzerland) · 2022Review
- The role of the gut microbiome in paediatric irritable bowel syndrome.AIMS microbiology · 2022Review
- Editorial: defining a microbial signature to predict non-response to a low FODMAP diet-a step closer or is it? Authors' reply.Alimentary pharmacology & therapeutics · 2021Article
- Evolution of Intestinal Microbiota of Asphyxiated Neonates Within 1 Week and Its Relationship With Neural Development at 6 Months.Frontiers in pediatrics · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundDietary fructans may worsen gastrointestinal symptoms in children with irritable bowel syndrome (IBS).
aimTo determine whether gut microbiome composition and function are associated with childhood IBS fructan-induced symptoms.
methodsFaecal samples were collected from 38 children aged 7-17 years with paediatric Rome III IBS, who previously completied a double-blind, randomised, placebo-controlled crossover (fructan vs maltodextrin) trial. Fructan sensitivity was defined as an increase of ≥30% in abdominal pain frequency during the fructan diet. Gut microbial composition was determined via 16Sv4 rDNA sequencing. LEfSe evaluated taxonomic composition differences. Tax4Fun2 predicted microbial fructan metabolic pathways.
resultsAt baseline, 17 fructan-sensitive (vs 21 fructan-tolerant) subjects had lower alpha diversity (q < 0.05) and were enriched in the genus Holdermania. In contrast, fructan-tolerant subjects were enriched in 14 genera from the class Clostridia. During the fructan diet, fructan-sensitive (vs tolerant) subjects were enriched in both Agathobacter (P = 0.02) and Cyanobacteria (P = 0.0001). In contrast, fructan-tolerant subjects were enriched in three genera from the Clostridia class. Comparing the fructan vs maltodextrin diet, fructan-sensitive subjects had a significantly increased relative abundance of Bifidobacterium (P = 0.02) while fructan-tolerant subjects had increased Anaerostipes (P = 0.03) during the fructan diet. Only fructan-sensitive subjects had a trend towards increased predicted β-fructofuranosidase during the fructan vs maltodextrin diet.
conclusionsFructan-sensitive children with IBS have distinct gut microbiome signatures. These microbiome signatures differ both at baseline and in response to a fructan challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.